Current Pharmacological Management in Juvenile Huntington’s Disease | Zendy

Lisa Robertson | Zendy; Helen Santini | Zendy; Kirsty O’Donovan | Zendy; Ferdinando Squitieri | Zendy; Roger A. Barker | Zendy; Maria Rakowicz | Zendy; G. Bernhard Landwehrmeyer | Zendy; Oliver Quarrell | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Current Pharmacological Management in Juvenile Huntington’s Disease

Author(s) -

Lisa Robertson,

Helen Santini,

Kirsty O’Donovan,

Ferdinando Squitieri,

Roger A. Barker,

Maria Rakowicz,

G. Bernhard Landwehrmeyer,

Oliver Quarrell

Publication year - 2012

Publication title -

plos currents

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.282

H-Index - 49

ISSN - 2157-3999

DOI - 10.1371/currents.rrn1304

Subject(s) - medicine , huntington's disease , juvenile , disease , presentation (obstetrics) , disease management , intensive care medicine , psychiatry , pediatrics , surgery , parkinson's disease , genetics , biology

Background: The clinical presentation of Juvenile Huntington’s Disease (JHD) can be very different from adult-onset HD with little evidence to guide symptomatic management. Aim: To survey the current use of pharmacological treatments for JHD. Methods: Patients were identified through the HD Association, Hospital Doctors and the European Huntington’s Disease Network REGISTRY study. Results: The most commonly prescribed agents were anti-psychotics (24/45), anti-depressants (17/45) and anti-parkinsonian medications (15/45). 5 patients were taking more than 8 medications. Conclusions: The most commonly prescribed group of medication was the anti-psychotic. Many patients were on multiple therapies, highlighting the need to rationalise medications.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research